T1	Participants 42 73	Southeastern Cancer Study Group
T2	Participants 157 288	20 phase I, II, and III clinical trials from 1979 to 1983 at 30 member institutions of the Southeastern Cancer Study Group (SECSG).
T3	Participants 313 413	new and commercially available drugs, as well as surgery and/or radiation therapy in 1,087 patients.
T4	Participants 451 460	18 agents
T5	Participants 466 501	one agent is still under evaluation
